Elrefio subcutaneous injection 44mg

Elrefio subcutaneous injection 44mg, manufactured by Pfizer, contains Erlanatamab (genetical recombination). This bispecific antibody is engineered to treat specific hematologic malignancies by targeting both CD3 on T-cells and a tumor-associated antigen on cancer cells, initiating T-cell-mediated cytotoxicity. It is supplied as 44mg in 1.1mL per bottle, with YJ code 4291470A1020.